NBC Securities Inc. Invests $46,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

NBC Securities Inc. bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report) in the third quarter, HoldingsChannel reports. The institutional investor bought 672 shares of the medical equipment provider’s stock, valued at approximately $46,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Fairfield Bush & CO. bought a new stake in Lantheus in the first quarter valued at about $177,000. Raymond James & Associates bought a new stake in Lantheus in the first quarter valued at about $856,000. Bank of New York Mellon Corp increased its holdings in Lantheus by 2.7% in the first quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider’s stock valued at $34,791,000 after purchasing an additional 16,422 shares during the last quarter. American Century Companies Inc. increased its holdings in Lantheus by 14.4% in the first quarter. American Century Companies Inc. now owns 19,235 shares of the medical equipment provider’s stock valued at $1,064,000 after purchasing an additional 2,427 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new position in Lantheus in the first quarter valued at about $354,000. Institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. William Blair cut Lantheus from an “outperform” rating to a “market perform” rating in a research note on Monday, December 18th. TheStreet cut Lantheus from a “b-” rating to a “c” rating in a research note on Monday, December 18th. Brookline Capital Management assumed coverage on Lantheus in a research note on Thursday, November 30th. They issued a “buy” rating and a $100.00 target price for the company. Finally, JMP Securities decreased their target price on Lantheus from $130.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, November 3rd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $108.14.

Get Our Latest Report on LNTH

Lantheus Stock Up 1.7 %

LNTH stock opened at $54.99 on Wednesday. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.37 and a quick ratio of 5.05. The stock has a market capitalization of $3.77 billion, a P/E ratio of 38.45 and a beta of 0.53. The business has a 50-day moving average of $61.76 and a 200-day moving average of $66.27. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $100.85.

Insider Buying and Selling

In related news, President Paul Blanchfield sold 1,500 shares of the company’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $67.96, for a total transaction of $101,940.00. Following the sale, the president now owns 88,651 shares in the company, valued at $6,024,721.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Lantheus news, CEO Mary Anne Heino sold 11,780 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $63.72, for a total value of $750,621.60. Following the sale, the chief executive officer now owns 317,687 shares in the company, valued at $20,243,015.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, President Paul Blanchfield sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $67.96, for a total value of $101,940.00. Following the completion of the sale, the president now owns 88,651 shares in the company, valued at approximately $6,024,721.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,962 shares of company stock worth $893,338. Corporate insiders own 1.50% of the company’s stock.

Lantheus Profile

(Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.

Featured Stories

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.